The Schepens Eye Research Institute. Inc.
Boston, MA Part of Partners Healthcare System Incorporated
- UEI
- XQQJEDK7JC21
- CAGE
- 1NUK9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Brigham & Womens Hospital Inc, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
KH2QJR76KMZ6
-
Parent
KH2QJR76KMZ6
- SAM.gov registration date
- Physical address
- 20 Staniford St, Boston, MA 02114, USA
- Website
- harvard.edu
- Employees
- 10K-50K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Consumer Discretionary
- Diversified Consumer Services
- Education Services
- Education
- SIC code
- 82 Educational Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The General Hospital Corporation | R01NS142225 | $116,281 | |
| The Johns Hopkins University | HT94252310589 | $645,982 | |
| The General Hospital Corporation | R01NS095640 | $120,561 | |
| President And Fellows Of Harvard College | UM1TR004408 | $98,500 | |
| The General Hospital Corporation | RM1NS132996 | $1,477,500 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
The Schepens Eye Research Institute Inc., a nonprofit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear and a subsidiary of Partners Healthcare System Incorporated, operates as a federal grant recipient conducting basic and translational vision research for the National Eye Institute, the Defense Health Agency, and related NIH components.
Schepens is primarily a grant recipient (194 of 201 awards, or 97 percent), with a heavy concentration in the National Eye Institute's Vision Research program (CFDA 93.867) and the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). The institute's recent award activity spans ophthalmic research across retinal disease, corneal pathology, glaucoma mechanisms, gene therapy, and medical countermeasures for chemical and blast ocular injury. Representative work includes a $506,030 Vision Research grant (awarded September 2026, completion April 2031) to develop open-source OCT data export and integration tools across seventeen U.S. institutions, addressing a critical barrier in ophthalmic research where proprietary imaging formats lock data in over ten vendor-specific storage systems; an $858,394 award (August 2026, completion July 2030) for multimodal foundation models combining vision-language AI with clinical notes to detect and predict progression of age-related macular degeneration, diabetic retinopathy, and glaucoma; and a $1.466 million Defense Health Agency grant (September 2025, completion August 2028) on topical oxygen therapy for pan-ocular chemical injury protection. The institute also received a $881,797 award (May 2026, completion April 2028) for mini-USH2A gene therapy development targeting Usher Syndrome Type 2A, the leading inherited cause of combined hearing and vision loss.
Customer concentration is dominated by the National Eye Institute and broader NIH funding. The top five customer agencies account for 83 percent of recent awards by count, with the National Eye Institute carrying 79 awards, general NIH carrying 54, and the Defense Health Agency placing 19 awards worth $3 million in combined potential value. Activity has remained steady, with eleven awards in 2022, sixteen in 2023, nine in 2024, twelve in 2025, and eight in the first nine months of 2026. Twenty-one awards face ultimate completion in the next twenty-four months, creating recompete exposure. Schepens holds a single named parent vehicle—an Indefinite Delivery Contract (DAMD1786C6170) with four associated task orders. Recent obligations substantially exceed potential values across the portfolio ($377.4 million obligated against $3.8 million potential value), a signal of mature, ongoing grant drawdowns rather than new procurement.
In its subcontractor role, Schepens works as a subawardee on familial dysautonomia research under a General Hospital Corporation prime (National Eye Institute), retinal ganglion cell transplantation work under a Johns Hopkins University prime, and genetic sequencing and iPSC analysis on an Alzheimer's disease study under a Brigham and Women's Hospital prime. The institute's work is performed primarily at its Boston, Massachusetts facility and across partner institutions including Massachusetts Eye and Ear, Harvard-affiliated medical centers, Tufts Medical Center, and Carroll Center for the Blind. Performance of work is in Boston with collaborations across domestic academic and research networks; the institute does not compete on contracts or manage commercial contract vehicles.
Quick answers
Is The Schepens Eye Research Institute. Inc. registered in SAM.gov?
Yes. The Schepens Eye Research Institute. Inc.'s SAM.gov registration is active through March 24, 2027.
How does The Schepens Eye Research Institute. Inc. rank among federal contractors?
The Schepens Eye Research Institute. Inc.'s parent company, Brigham & Womens Hospital Inc, ranked #10 in PSC Q502, #13 in PSC Q523 and #21 in PSC B529 in FY2025.
What is The Schepens Eye Research Institute. Inc.'s most recent federal award?
The Schepens Eye Research Institute. Inc.'s most recent federal grant award is Export and integration of ophthalmic optical coherence tomography data across institutions (OCT) (R01EY039476), from National Eye Institute (NIH), on September 1, 2026.
On GovTribe
See The Schepens Eye Research Institute. Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors